Surveys indicate that one form of acceptable male hormonal contraception would consist of injections given at 2- to 3-month intervals. This report describes a study of depot medroxyprogesterone acetate (DMPA) and testosterone undecanoate (TU) injected at 8-wk intervals for suppression of spermatogenesis in healthy Chinese men. After screening, 30 healthy volunteers were enrolled and randomly as...

This retrospective study looked at the bone mass density of women using combined oral contraception (n = 59), depot-medroxyprogesterone acetate (DMPA) (n = 34) or controls (n = 62) who had not used steroid contraception for 6 months. The groups were matched for body mass index, age, smoking, alcohol consumption, caffeine consumption and exercise. There was no matching for family history nor was...

Galactorrhea is rarely mentioned as a possible side effect of the use of Depot-Medroxyprogesterone Acetate (DMPA). Over the last few years, we have noticed an increased number of patients complaining of galactorrhea. A review of clinical data showed that between 1999 and 2005, 360 adolescents in our clinic used DMPA for at least 6 months. After medical follow-up, 13 (3.6%) of these patients wer...

BACKGROUND Depot medroxyprogesterone acetate (DMPA) has been linked to human immunodeficiency virus type 1 (HIV-1) acquisition. METHODS Vaginal microbiota of women using DMPA for up to 2 years were cultured. Mucosal immune cell populations were measured by immunohistological staining. RESULTS Over 12 months, the proportion with H2O2-positive lactobacilli decreased (n = 32; 53% vs 27%; P = ....

currently using long-acting injectable contraceptives, mostly in developing countries, and the number of users is increasing. It is generally believed that the popularity of such methods would considerably increase if they were further improved. Table 1 describes the current status of injectable contraceptives which are either available in the market or under development. Injectable hormonal co...

BACKGROUND In vitro, animal, biological and observational clinical studies suggest that some hormonal methods, particularly depot medroxyprogesterone acetate - DMPA, may increase women's risk of HIV acquisition. DMPA is the most common contraceptive used in many countries worst affected by the HIV epidemic. To provide robust evidence for contraceptive decision-making among women, clinicians and...

This retrospective study looked at the bone mass density of women using combined oral contraception (n = 59), depot-medroxyprogesterone acetate (DMPA) (n = 34) or controls (n = 62) who had not used steroid contraception for 6 months. The groups were matched for body mass index, age, smoking, alcohol consumption, caffeine consumption and exercise. There was no matching for family history nor was...

Normal postpartum women, who had a spontaneous vaginal delivery of one full-term male infant, free of congenital abnormalities and other diseases, were recruited for this study. Thirteen women received 150 mg depot-medroxy-progesterone acetate (DMPA), intramuscularly on days 42 + 1 and 126 + 1 postpartum. Infants of nine mothers, who did not receive DMPA, served as controls. Blood samples were ...

Background Hysterosalpingram (HSG) evaluation of tubal patency is typically performed in the follicular phase, but data to support this timing are lacking. Purpose To determine whether menstrual cycle phase or hormonal treatments affect observation of tubal patency during HSG. Material and Methods Ten participants underwent repeated HSG examinations: during the follicular and luteal phase of a ...

OBJECTIVES To evaluate the effect of hormonal contraception including combined oral contraceptives (COCs), and the injectable progestins depo-medroxyprogesterone acetate (DMPA) and norethisterone enanthate (Net-En) on the risk of HIV acquisition among women in South Africa. DESIGN/METHODS We analyzed data from 5567 women aged 16-49 years participating in the Carraguard Phase 3 Efficacy Trial....